189 related articles for article (PubMed ID: 37957586)
1. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
[TBL] [Abstract][Full Text] [Related]
2. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
[TBL] [Abstract][Full Text] [Related]
3. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
[TBL] [Abstract][Full Text] [Related]
4. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
5. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.
Pignolo RJ; Baujat G; Brown MA; De Cunto C; Di Rocco M; Hsiao EC; Keen R; Al Mukaddam M; Sang KLQ; Wilson A; White B; Grogan DR; Kaplan FS
Orphanet J Rare Dis; 2019 May; 14(1):98. PubMed ID: 31053156
[TBL] [Abstract][Full Text] [Related]
6. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).
Smilde BJ; Stockklausner C; Keen R; Whittaker A; Bullock AN; von Delft A; van Schoor NM; Yu PB; Eekhoff EMW
BMC Musculoskelet Disord; 2022 Jun; 23(1):519. PubMed ID: 35650602
[TBL] [Abstract][Full Text] [Related]
7. Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.
Lindborg CM; Al Mukaddam M; Baujat G; Cho TJ; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao EC; Morhart R; de Ruiter R; Scott C; Seemann P; Szczepanek M; Tabarkiewicz J; Pignolo RJ; Kaplan FS
Clin Orthop Relat Res; 2023 Dec; 481(12):2447-2458. PubMed ID: 37156007
[TBL] [Abstract][Full Text] [Related]
8. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
9. The Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ): A patient-reported, disease-specific measure.
Pignolo RJ; Kimel M; Whalen J; Kawata AK; Artyomenko A; Kaplan FS
Bone; 2023 Mar; 168():116642. PubMed ID: 36526263
[TBL] [Abstract][Full Text] [Related]
10. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
Elife; 2018 Sep; 7():. PubMed ID: 30226468
[TBL] [Abstract][Full Text] [Related]
11. Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP).
Lindborg CM; Brennan TA; Wang H; Kaplan FS; Pignolo RJ
Bone; 2018 Apr; 109():153-157. PubMed ID: 28963080
[TBL] [Abstract][Full Text] [Related]
12. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP).
Hsiao EC; Di Rocco M; Cali A; Zasloff M; Al Mukaddam M; Pignolo RJ; Grunwald Z; Netelenbos C; Keen R; Baujat G; Brown MA; Cho TJ; De Cunto C; Delai P; Haga N; Morhart R; Scott C; Zhang K; Diecidue RJ; Friedman CS; Kaplan FS; Eekhoff EMW
Br J Clin Pharmacol; 2019 Jun; 85(6):1199-1207. PubMed ID: 30281842
[TBL] [Abstract][Full Text] [Related]
13. Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva.
Warner SE; Kaplan FS; Pignolo RJ; Smith SE; Hsiao EC; De Cunto C; Di Rocco M; Harnett K; Grogan D; Genant HK
Calcif Tissue Int; 2021 Dec; 109(6):615-625. PubMed ID: 34331548
[TBL] [Abstract][Full Text] [Related]
14. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
15. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
Towler OW; Shore EM; Kaplan FS
Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
[TBL] [Abstract][Full Text] [Related]
16. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.
Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
[TBL] [Abstract][Full Text] [Related]
17. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.
Eekhoff EMW; Botman E; Coen Netelenbos J; de Graaf P; Bravenboer N; Micha D; Pals G; de Vries TJ; Schoenmaker T; Hoebink M; Lammertsma AA; Raijmakers PGHM
Bone; 2018 Apr; 109():143-146. PubMed ID: 28826841
[TBL] [Abstract][Full Text] [Related]
18. Fibrodysplasia ossificans progressiva: Review and research activities in Japan.
Haga N; Nakashima Y; Kitoh H; Kamizono J; Katagiri T; Saijo H; Tsukamoto S; Shinoda Y; Sawada R; Nakahara Y
Pediatr Int; 2020 Jan; 62(1):3-13. PubMed ID: 31774601
[TBL] [Abstract][Full Text] [Related]
19. Clinical staging of Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ; Kaplan FS
Bone; 2018 Apr; 109():111-114. PubMed ID: 28943457
[TBL] [Abstract][Full Text] [Related]
20. The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.
Pignolo RJ; Bedford-Gay C; Liljesthröm M; Durbin-Johnson BP; Shore EM; Rocke DM; Kaplan FS
J Bone Miner Res; 2016 Mar; 31(3):650-6. PubMed ID: 27025942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
